Alcoholism

Alcoholism emerges in this history not only as a disorder of drinking but as a crisis of meaning, connection, and agency. Psychedelic treatment has repeatedly been proposed as a way to interrupt that crisis: a carefully supported experience might provoke a spiritual or psychological shift that ordinary treatment has not achieved. The record is striking but uneven, moving from early LSD experiments and Alcoholics Anonymous debates to modern trials whose promising results remain preliminary. Across these settings, the central question is not simply whether a drug works, but how the experience, the people guiding it, and the framework around it contribute to change.

Early experiments and the conversion hypothesis

In the early 1950s, Humphry Osmond and Abram Hoffer were studying LSD at the Saskatchewan Mental Hospital in Weyburn. Their initial interest was psychotomimetic: because LSD could produce effects resembling mental illness, they hoped it might illuminate the biochemistry of psychiatric disorders. But their attention shifted toward the experience itself and its possible therapeutic value. During a late-night discussion in an Ottawa hotel room in 1953, they connected LSD’s sometimes terrifying effects with delirium tremens, the prolonged delirium that can accompany alcohol withdrawal. Some recovering alcoholics described the ordeal as a conversion experience that helped them remain sober. Osmond and Hoffer wondered whether a controlled, drug-induced delirium might similarly shock a patient into sobriety.

They tested the proposal over the next decade with more than seven hundred alcoholics. Their reports suggested that roughly half of the volunteers became sober and remained so for at least several months. The approach treated a single high-dose LSD session as a possible turning point, rather than relying only on a sequence of ordinary therapeutic appointments. Just as important was the researchers’ growing conviction that the decisive therapeutic ingredient might not be the chemical by itself: the subjective experience could be central to the treatment. This emphasis on what patients felt challenged a behaviorist outlook that privileged observable behavior and treated inner experience as scientifically inaccessible.

The theory did not neatly match the reports. Although some volunteers experienced hallucinations, paranoia, or anxiety, many described positive states, including a feeling of unity with the world, heightened perception, and the ability to view themselves more objectively. For many patients, the core of the session seemed closer to transcendence or spiritual insight than to simulated madness. Osmond and Hoffer consequently questioned whether the delirium-tremens analogy, and the broader psychotomimetic model, could adequately explain what had happened.

They also learned that the session’s surroundings and human company mattered. An engaged, empathetic therapist—ideally one with personal experience of LSD—could help avert a bad experience. The researchers suspected that some adverse reactions might be encouraged by a sterile clinical environment and a disengaged, white-coated observer. Though the later terminology of set and setting was not yet in use, the practical insight was already emerging: treatment outcomes could depend on more than the administered drug.

Policy, replication, and contested evidence

By the end of the 1950s, LSD was widely regarded in North America as a promising treatment for alcohol addiction. The Government of Saskatchewan helped establish LSD therapy as a standard treatment option for alcoholics in the province. Yet the results appeared so favorable that other clinicians doubted their credibility. In the early 1960s, the Addiction Research Foundation in Toronto attempted a more controlled replication, seeking to separate the drug’s effects from other influences.

The Toronto clinicians placed patients in neutral rooms and told staff not to engage with them during the sessions except to administer questionnaires. Some volunteers were restrained or blindfolded, sometimes both. The results did not reproduce the Saskatchewan group’s reported success, and several participants endured frightening experiences. Critics took the outcome as evidence that the treatment was less effective under rigorous controls; its supporters saw the same experiment as showing how essential the therapeutic environment was. The disagreement exposes a methodological difficulty that persisted in later research: isolating a drug from the expectations, relationships, and surroundings that shape its effects may remove part of the treatment being evaluated.

For decades, the evidence remained difficult to interpret. Thousands of people had received LSD or other psychedelics for alcoholism in the 1950s and 1960s, but many studies were poorly designed or weakly controlled. Results tended to look better when conducted by sympathetic therapists, particularly those who had taken LSD themselves, and worse when inexperienced investigators gave large doses without attending to the session’s context. A 2012 meta-analysis brought greater structure to the record by combining the six best randomized controlled studies from the 1960s and 1970s, involving more than five hundred patients. It found a statistically robust and clinically significant beneficial effect on alcohol misuse after a single LSD dose, lasting as long as six months. The finding strengthened the case that the early work contained a real therapeutic signal, while leaving open why the treatment had been so thoroughly neglected.

Alcoholics Anonymous and spiritual awakening

The possibility that a drug might help someone achieve a life-changing spiritual experience resonated with Bill Wilson, cofounder of Alcoholics Anonymous. Wilson associated his own sobriety with a mystical experience on belladonna, administered at Towns Hospital in Manhattan in 1934. In the mid-1950s, after learning about Osmond and Hoffer’s work, he wondered whether LSD could help recovering alcoholics undergo a similar awakening.

Beginning in 1956, Wilson took several LSD sessions in Los Angeles with Sidney Cohen and Betty Eisner. Those experiences persuaded him that LSD could reliably occasion the spiritual awakening he considered important to sobriety. They also reinforced his view that the experience was not equivalent to delirium tremens, further weakening the early theory that the treatment worked by reproducing withdrawal-induced madness. Wilson thought LSD therapy might have a place in Alcoholics Anonymous, but the fellowship’s board strongly opposed the idea. Its members feared that endorsing a mind-altering substance would blur the organization’s identity and message.

The apparent contradiction—using a drug to support sobriety—made more sense within the fellowship’s emphasis on surrendering self-reliance, acknowledging powerlessness, and turning attention toward a higher power and supportive community. In this account, addiction narrows a person’s attachments until the substance displaces other relationships and purposes. Psychedelic therapy and Alcoholics Anonymous differed in practice, but both offered a framework in which the self could become less dominant and connection could be restored. The spiritual framing was not merely an explanation added after treatment: it shaped what practitioners hoped the experience might make possible.

Renewed research and individual outcomes

Research into psychedelic treatment for addiction resumed alongside broader clinical efforts to revisit work interrupted by cultural and institutional pressures. A 2015 pilot study at the University of New Mexico combined psilocybin sessions with motivational enhancement therapy, a form of cognitive behavioral therapy designed for addiction. Ten alcoholics took part. The psychotherapy alone had little effect on drinking behavior, while drinking decreased significantly after the psilocybin session; the change persisted through thirty-six weeks of follow-up. Lead investigator Michael Bogenschutz reported a strong correlation between the strength of the experience and its effect on drinking. The result justified a larger phase-two trial involving 180 volunteers, which Bogenschutz was conducting at New York University in collaboration with Stephen Ross and Jeffrey Guss.

The account also complicates the clean success narrative that can attach itself to a promising pilot study. One participant, identified as Terry McDaniels, had lived with memory problems after her former husband struck her head with a cast-iron skillet. She had tried rehabilitation, therapy, and Alcoholics Anonymous, repeatedly returning to drinking, and had never previously used a psychedelic. During her psilocybin session, she first saw her children and wept for the life they had not had; the experience later became awe-inspiring and peaceful. Her drinking did not end completely. She had recently gone on a one-day binge after an argument with her daughter, but before treatment her binges could last two weeks and involve hard liquor until she blacked out. For McDaniels, the shorter, less severe episode represented progress, not a total cure. Her story makes visible a measure of change that a simple sober-or-not distinction would miss.

Ross described alcoholism as a spiritual disorder in which a person can lose connection to everything but the substance, until even a spouse or children no longer outweigh the bottle. That formulation aligns with the reported aim of psychedelic treatment: not to substitute one chemical for another, but to catalyze an experience that may restore meaning, alter patterns of thought, or reopen relationships. It remains an interpretation of how treatment might help, rather than proof that spiritual experience alone accounts for the changes.

Treatment context and the limits of medicalization

The renewed research does not make the scientific problem disappear. Participants can often tell whether they received psilocybin or a placebo, and their guides may recognize it too, making conventional blinding difficult. Researchers must also contend with the influence of expectations, therapists, and session conditions. If a drug’s apparent benefit partly depends on the experience it occasions and the setting in which it is administered, those influences cannot easily be separated from pharmacology without changing the intervention itself.

This difficulty reflects a deeper professional and cultural tension. Psychedelic therapy challenges models built around repeated appointments or daily medication: it may involve one high-dose session, yet require substantial preparation, extended therapist presence, and subsequent integration. Its spiritual dimensions further complicate its acceptance within medicine. Charles Grob described the approach as a form of applied mysticism, while other researchers have argued that the therapeutic use of psychedelics should learn from practices that carefully organize the experience and its surrounding context.

The treatment’s return to respectable research has therefore not settled who should receive it, who should guide it, or whether its use should remain confined to clinical care. Advocates of medicalization see formal trials and regulation as routes to safe acceptance; others worry that limiting psychedelics to patients and physicians would exclude broader spiritual or personal uses. The book’s account of underground guides adds another dimension: some practitioners continued psychedelic-assisted work after prohibition, despite legal and professional risks, and emphasized confidentiality, carefully defined agreements, and the guide’s own familiarity with the medicine. These practices are not presented as interchangeable with regulated trials, but they demonstrate how treatment has persisted beyond authorized institutions.

For alcoholism, the historical lesson is consequently double-edged. The trials and meta-analysis support renewed investigation, and the modern pilot offers a concrete, if small, signal of benefit. At the same time, the record resists the idea of a simple drug effect that can be detached from setting, human support, and the patient’s understanding of the experience. Whether described as spiritual awakening, psychological change, or a clinical response, improvement is portrayed as a process whose meaning and durability require more than the session itself.